Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series
Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series
复制标题
DOI：
10.1186/1471-5945-5-9
复制
发表时间：
2005-08-18
期刊：
影响因子：
--
通讯作者：
Barnetson, Ross StC
中科院分区：
文献类型：
--
作者：
Lowes, Michelle A.;Turton, James A.;Barnetson, Ross StC
背景资料：严重的寻常型银屑病可以是非常困难的治疗，在某些患者，即使与较新的生物疗法提供today.Case介绍：我们提出了两个严重的慢性斑块状银屑病患者谁收到了许多系统的抗银屑病治疗不同的结果。两人对依法利珠单抗（抗CD 11 a）的初始治疗反应良好，但在错过一剂后病情突然发作。然而，在疾病稳定后，两名患者反应良好，重新引入依法利珠单抗，一名患者需要同时治疗英夫利昔单抗（抗TNF-α）。结论：这些情况下，提出了表征这种“耀斑”反应，并告知医疗保健提供者依法利珠单抗仍然可以管理后，疾病耀斑，并再次可能是一个成功的治疗。
Background: Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even with the newer biological therapies available today.Case presentations: We present two patients with severe chronic plaque psoriasis who received numerous systemic anti-psoriatic therapies with varied results. Both responded well to initial treatment with efalizumab (anti-CD11a), but then experienced a flare of their disease after missing a dose. However, after disease stablization, both patients responded well to re-introduction of efalizumab, one patient requiring concurrent treatment with infliximab (anti-TNF-alpha).Conclusion: These cases are presented to characterize this "flare" reaction, and to inform health care providers that efalizumab can still be administered after disease flare, and again may be a successful therapy.